Abstract

In the upfront treatment of multiple myeloma, the addition of triple therapy with bortezomib, lenalidomide, and dexamethasone (RVD) for consolidation or a second autologous hematopoietic cell transplant is not superior to a single transplant followed by lenalidomide maintenance, according to the largest randomized controlled trial of post-transplant therapy for multiple myeloma ever conducted in the U.S.